Donor Variability in Ex Vivo Human Tissue Studies: Challenge, Feature, or Translational Advantage

Biological variability is an inherent characteristic of human physiology. Within preclinical drug discovery, variability is often treated as a confounding factor to be minimized.¹ Highly standardized cell lines, genetically homogeneous animal models, and tightly controlled in vitro systems are designed to reduce experimental noise and improve reproducibility. While these systems provide important mechanistic insights, they frequently lack one critical feature of clinical reality: patient heterogeneity.²

Ex vivo human tissue models occupy a distinct and increasingly important space in translational research because they preserve this heterogeneity. Donor variability, the biological differences between individual tissue donors, is not an experimental artifact, but rather a reflection of real-world patient populations. The question, therefore, is not whether donor variability should exist, but how it should be interpreted and strategically leveraged.³

The Biological Basis of Donor Variability

Human tissue samples inherently differ based on age, sex, genetic background, environmental exposure, disease stage, co-morbidities, and prior pharmacological treatment.⁴ These factors influence receptor expression, inflammatory tone, contractile responsiveness, ion channel activity, metabolic function, and tissue remodeling. In diseased tissue particularly, inter-donor variability may reflect differences in disease endotype or severity, which are increasingly recognized as key determinants of therapeutic response.⁵

Unlike immortalized cell lines or induced models of disease, fresh human tissue maintains native architecture, cell–cell interactions, extracellular matrix composition, and endogenous signaling networks. Consequently, functional readouts, whether electrophysiological responses, cytokine release profiles, or smooth muscle contractility, often display a range of baseline values and compound sensitivities across donors. While this may increase statistical complexity, it also enhances biological fidelity.⁶

Variability and Translational Predictivity

Clinical trial outcomes consistently demonstrate that patients do not respond uniformly to therapeutic intervention. In complex, multifactorial diseases such as inflammatory bowel disease, asthma, overactive bladder, cardiovascular disease, or dermatological inflammatory disorders, response heterogeneity is the rule rather than the exception. Compounds that demonstrate robust efficacy in simplified preclinical systems may fail when confronted with the biological diversity of a patient population.⁷

Ex vivo human tissue studies introduce this diversity earlier in the development pipeline. Observing differential responsiveness across donors can provide early indication of potential responder and non-responder subgroups. This information may inform biomarker strategies, patient stratification approaches, or mechanistic refinement prior to clinical advancement. Rather than obscuring signal, variability can illuminate clinically relevant distinctions that would otherwise remain undetected.⁸

Importantly, incorporating multiple donors into study design mitigates the risk of advancing compounds that demonstrate efficacy only within narrow biological contexts. A therapeutic candidate that performs consistently across a heterogeneous donor panel provides stronger translational confidence than one validated in a homogeneous system.⁹

Scientific Rigor in the Context of Variability

The presence of variability does not preclude rigor. On the contrary, it demands it. Robust ex vivo study design requires careful donor characterization, standardized tissue procurement and handling protocols, and clearly defined functional endpoints. Statistical analysis must account for inter-donor variance, often through paired experimental designs or mixed-effects modeling approaches that distinguish biological variability from technical variability.

At REPROCELL, donor metadata, including demographic and clinical parameters, are integrated into study interpretation wherever appropriate. Consistency in tissue preparation, assay conditions, and endpoint quantification ensures that observed differences reflect genuine biological diversity rather than procedural inconsistency. This framework allows variability to be contextualized, quantified, and interpreted scientifically.¹⁰

Variability as an Asset in Precision Medicine

The increasing emphasis on precision medicine further reframes donor variability as an opportunity rather than a limitation. As therapeutic development shifts toward targeted interventions and stratified patient populations, understanding heterogeneity at the tissue level becomes essential. Ex vivo human models offer a platform in which differential pharmacological responses can be explored directly within disease-relevant biology.¹¹

In this context, variability may reveal mechanistic subtypes, differential pathway activation, or altered receptor pharmacodynamics across donors. These findings can support hypothesis generation, refine target validation strategies, and ultimately contribute to more informed clinical trial design.

Reconsidering the Paradigm

Efforts to eliminate biological variability may inadvertently distance preclinical research from clinical reality. While reductionist systems retain value for mechanistic dissection, translational confidence depends on models that reflect the complexity of human disease. Ex vivo human tissue studies acknowledge that heterogeneity is intrinsic to biology, and that successful therapeutics must perform within that complexity.

Donor variability, therefore, should not be viewed solely as a challenge to be controlled. When approached with appropriate scientific rigor, it becomes a feature of the model and, importantly, a translational advantage. By integrating diverse, well-characterized human tissue into preclinical evaluation, researchers can generate data that are not only reproducible, but also clinically meaningful.

At REPROCELL, we believe that embracing biological complexity strengthens drug discovery. 

References:

1. Kira D McEntire, Matthew Gage, Richard Gawne, Michael G Hadfield, Catherine Hulshof, Michele A Johnson, Danielle L Levesque, Joan Segura, Noa Pinter-Wollman, Understanding Drivers of Variation and Predicting Variability Across Levels of Biological Organization, Integrative and Comparative Biology, Volume 61, Issue 6, December 2021, Pages 2119–2131, https://doi.org/10.1093/icb/icab160 
2. Chongbei Zhao (2023) Cell culture: in vitro model system and a promising path to in vivo applications, Journal of Histotechnology, 46:1, 1-4, DOI: 10.1080/01478885.2023.2170772 
3. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Regenerative Medicine; Beachy SH, Wizemann T, Hackmann M, editors. Exploring Sources of Variability Related to the Clinical Translation of Regenerative Engineering Products: Proceedings of a Workshop. Washington (DC): National Academies Press (US); 2019 Mar 21. 4, Addressing Variability in Donor Tissues and Cells.  https://www.ncbi.nlm.nih.gov/books/NBK544028/ 
4. “MRC Ethics Series Human Tissue and Biological Samples for Use in Research:” UKVI, www.ukri.org/wp-content/uploads/2021/08/MRC-0208212-Human-tissue-and-biological-samples-for-use-in-research.pdf. 
5. Beetler, D.J., Giresi, P., Xu, V. et al. Donor-dependent heterogeneity in therapeutic effects of adipose tissue extracellular vesicles. Cell Commun Signal 24, 4 (2026). https://doi.org/10.1186/s12964-025-02563-8 
6.“What Makes a Translationally Relevant Functional Readout?” Home, Diagnostic Biochips, 18 Feb. 2026, diagnosticbiochips.com/our-story/blog/what-makes-a-translationally-relevant-functional-readout.
7. Heneghan, C., Goldacre, B. & Mahtani, K.R. Why clinical trial outcomes fail to translate into benefits for patients. Trials 18, 122 (2017). https://doi.org/10.1186/s13063-017-1870-2 
8. “Chapter 12: Interpreting Donor Test Results.” GOV.UK, www.gov.uk/government/publications/guidance-on-the-microbiological-safety-of-human-organs-tissues-and-cells-used-in-transplantation/chapter-12-interpreting-donor-test-results.
9. Gu, Y., Yang, R., Zhang, Y. et al. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Mol Biomed 6, 2 (2025). https://doi.org/10.1186/s43556-024-00239-2 
10. Mosedale, James. “Optimizing Experimental Design in in Vivo Research.” Ichorbio, Magento2 Store, 7 Oct. 2024, ichor.bio/resources/optimizing-experimental-design-in-in-vivo-research-a-comprehensive-review.
11. Ying Jiang, Jian Wang, Aihua Sun, Hongxing Zhang, Xiaobo Yu, Weijie Qin, Wantao Ying, Yanchang Li, Cheng Chang, Xiaowen Wang, Linhai Xie, Wei Liu, Jialin Liu, Xiaomei Zhang, Qunjiao Yan, Yu Zou, Chuanping Zhao, Haofan Sun, Jian Zhang, Shicheng Su, Qiang Gao, Fuchu He, The coming era of proteomics-driven precision medicine, National Science Review, Volume 12, Issue 8, August 2025, nwaf278, https://doi.org/10.1093/nsr/nwaf278